Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP)

NCT03135548 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03135548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03135548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
May 30, 2017
Completion date
November 14, 2018
Enrollment
59 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis